乳酸镁 | 18917-93-6

• 物质功能分类: 有机原料 - 有机金属盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 乳酸镁
• 中文别名: 三水乳酸镁；L-乳酸镁；α-羟基丙酸镁
• 英文名称: Magnesium lactate
• 英文别名: magnesium;2-hydroxypropanoate
• CAS: 18917-93-6
• 化学式: C6H10MgO6
• 分子量: 202.45
• InChiKey: OVGXLJDWSLQDRT-UHFFFAOYSA-L

物化性质

• 熔点：
  41°C
• 溶解度：
  微溶于水，溶于沸水，几乎不溶于乙醇（96%）。
• LogP：
  -0.698 (est)
• 稳定性/保质期：

  在常温常压下稳定，应避免接触酸。

计算性质

• 辛醇/水分配系数(LogP)：
  -4.15
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• TSCA：
  Yes
• 安全说明：
  S22,S24/25
• WGK Germany：
  1
• RTECS号：
  OD5660000
• 海关编码：
  2918110000

SDS

---

Section 1. Chemical Product and Company Identification
Magnesium Lactate Catalog
Common Name/
Number(s).
Trade Name
CAS# 18971-93-6
Manufacturer
RTECS OD560000
SPECTRUM QUALITY PRODUCTS INC.
TSCA TSCA 8(b) inventory:
Magnesium Lactate
Commercial Name(s) Not available.
CI# Not available.
Synonym Not available.
IN CASE OF EMERGENCY
Magnesium Lactate
Chemical Name
Chemical Family Not available. CALL [phone]
C6-H10-Mg-O6
Chemical Formula
SPECTRUM QUALITY PRODUCTS INC.

---

Section 2.Composition and Information on Ingredients
Exposure Limits
TWA (mg/m3) STEL (mg/m3) CEIL (mg/m3)
Name CAS # % by Weight
1) Magnesium Lactate 18971-93-6 100
Toxicological Data Magnesium Lactate:
on Ingredients ORAL (LD50): Acute: 2000 mg/kg [Rat].

---

Section 3. Hazards Identification
Potential Acute Health Effects Hazardous in case of eye contact (irritant), of inhalation.
Potential Chronic Health CARCINOGENIC EFFECTS: Classified 4 (No evidence.) by NTP, None. by OSHA, None. by NIOSH.
MUTAGENIC EFFECTS: Not available.
Effects
TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure is not known to aggravate medical condition.
Magnesium Lactate

---

Section 4. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at
least 15 minutes. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash
clothing before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Serious Skin Contact Not available.
Inhalation If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Serious Inhalation Not available.
Ingestion Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Serious Ingestion Not available.

---

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Flash Points Not available.
Flammable Limits Not available.
These products are carbon oxides (CO, CO2). Some metallic oxides.
Products of Combustion
Fire Hazards in Presence of Not available.
Various Substances
Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available.
of Various Substances Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media SMALL FIRE: Use DRY chemical powder.
and Instructions LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Special Remarks on Not available.
Fire Hazards
Special Remarks on Explosion Not available.
Hazards

---

Section 6. Accidental Release Measures
Small Spill Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by
spreading water on the contaminated surface and dispose of according to local and regional authority
requirements.
Large Spill
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water
on the contaminated surface and allow to evacuate through the sanitary system.
Magnesium Lactate

---

Section 7. Handling and Storage
Precautions Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire risk, evaporate the
residue under a fume hood. Ground all equipment containing material. Do not ingest. Do not breathe dust.
Avoid contact with eyes. Wear suitable protective clothing. In case of insufficient ventilation, wear suitable
respiratory equipment. If ingested, seek medical advice immediately and show the container or the label.
Storage Keep container tightly closed. Keep container in a cool, well-ventilated area.

---

Section 8. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Splash goggles. Lab coat.
Personal Protection in Case of Splash goggles. Full suit. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a
a Large Spill specialist BEFORE handling this product.
Exposure Limits Not available.

---

Section 9. Physical and Chemical Properties
Physical state and appearance Solid. Odor Not available.
Not available.
Taste
Molecular Weight Not available.
Not available.
Color
Not available.
pH (1% soln/water)
Boiling Point Not available.
Not available.
Melting Point
Critical Temperature Not available.
Specific Gravity Not available.
Not applicable.
Vapor Pressure
Vapor Density Not available.
Not available.
Volatility
Odor Threshold Not available.
Water/Oil Dist. Coeff. Not available.
Ionicity (in Water) Not available.
Dispersion Properties Not available.
Solubility Not available.

---

Section 10. Stability and Reactivity Data
Stability The product is stable.
Instability Temperature Not available.
Conditions of Instability Not available.
Incompatibility with various Not available.
substances
Corrosivity Not available.
Magnesium Lactate
Special Remarks on Not available.
Reactivity
Special Remarks on Not available.
Corrosivity
Polymerization Will not occur.

---

Section 11. Toxicological Information
Routes of Entry Eye contact. Inhalation. Ingestion.
Toxicity to Animals Acute oral toxicity (LD50): 2000 mg/kg [Rat].
Chronic Effects on Humans CARCINOGENIC EFFECTS: Classified 4 (No evidence.) by NTP, None. by OSHA, None. by NIOSH.
Other Toxic Effects on Hazardous in case of inhalation.
Humans
Special Remarks on
Not available.
Toxicity to Animals
Special Remarks on Not available.
Chronic Effects on Humans
Special Remarks on other Not available.
Toxic Effects on Humans

---

Section 12. Ecological Information
Ecotoxicity Not available.
BOD5 and COD Not available.
Possibly hazardous short term degradation products are not likely. However, long term degradation products may
Products of Biodegradation
arise.
The products of degradation are less toxic than the product itself.
Toxicity of the Products
of Biodegradation
Special Remarks on the Not available.
Products of Biodegradation

---

Section 13. Disposal Considerations
Waste Disposal

---

Section 14. Transport Information
DOT Classification Not a DOT controlled material (United States).
Not applicable.
Identification
Not applicable.
Special Provisions for
Transport
DOT (Pictograms)
Magnesium Lactate

---

Section 15. Other Regulatory Information and Pictograms
TSCA 8(b) inventory: Magnesium Lactate
Federal and State
Regulations
California
Proposition 65
Warnings
Other Regulations EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
WHMIS (Canada) Not controlled under WHMIS (Canada).
Other Classifications
DSCL (EEC)
R22- Harmful if swallowed.
R36- Irritating to eyes.
Health Hazard
HMIS (U.S.A.) 2 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
2 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
j
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG (Canada)
(Pictograms)
ADR (Europe)
(Pictograms)
Protective Equipment
Not applicable.
Lab coat.
Not applicable.
Splash goggles.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

鉴别试验

• 试样与水振摇30分钟后溶于水中；几不溶于乙醇。按OT-42方法测定。
• 镁盐试验（IT-21）呈阳性。
• 乳酸盐试验（IT-20）呈阳性。
• 比旋光度：按常规方法测定，试样液为3g/100ml（干基计）。

含量分析

精确称取预经干燥的试样约0.5g，溶于25mL水中，加入5mL氨一氯化铵缓冲液（TS-12），再加0.1mL铬黑试液（TS-97）。用0.05mol/L EDTA二钠滴定至蓝色。每毫升0.05mol/L EDTA二钠相当于乳酸镁[Mg(C3H5O3)2]10.12mg。

毒性

ADI不作限制性规定（FAO/WHO，2001）。

用途

用作食品添加剂，广泛用于食品、饮料、奶制品、面粉、营养液和制药等领域。

反应信息

• 作为反应物：
  描述：

  钙 、 氢氧化镁 、 乳酸镁 、 盐酸 生成 乳酸 、 氯化镁
  参考文献：
  名称：

  Process for the preparation of lactic acid or lactate from a magnesium lactate comprising medium

  摘要：

  本发明涉及一种改进的工艺，用于从含有乳酸镁的介质中制备乳酸和/或乳酸盐。在该工艺中，将乳酸镁与钠、钙和/或铵的氢氧化物在pH范围为9至12之间，优选在9.9至11之间反应，以形成钠、钾、钙和/或氨的乳酸盐和镁氢氧化物。使用本发明的工艺形成了乳酸盐和镁氢氧化物。关键是在特定的pH范围内进行所谓的SWAP反应：发现在pH范围为9至12之间进行SWAP反应时，会形成镁氢氧化物颗粒，这些颗粒可以轻松地从形成的乳酸盐溶液中分离出来。

  公开号：

  US07705180B2
• 作为产物：
  描述：

  乳酸 生成 乳酸镁
  参考文献：
  名称：

  ECONOMU, V.

  摘要：

  DOI：

文献信息

• [EN] 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS<br/>[FR] COMPOSÉS 3,5-DIAMINO -6-CHLORO-N-(N- (4-PHÉNYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE
  申请人：PARION SCIENCES INC

  公开号：WO2014099673A1

  公开（公告）日：2014-06-26

  The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

  本发明涉及以下化合物的公式：或其药学上可接受的盐，用作钠通道阻滞剂，以及含有这些化合物的组合物，制备这些化合物的方法，以及在促进粘膜表面水合和治疗包括囊性纤维化、慢性阻塞性肺病、哮喘、支气管扩张、急性和慢性支气管炎、肺气肿和肺炎等疾病的治疗方法。
• CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY
  申请人：Parion Sciences, Inc.

  公开号：US20140171447A1

  公开（公告）日：2014-06-19

  This invention provides compounds of the formula I: and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.

  这项发明提供了式I的化合物及其药用盐，可用作钠通道阻滞剂，包含这些化合物的组合物，以及用于这些化合物的治疗方法和用途，以及制备这些化合物的方法。
• [EN] AMINO ACID DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS<br/>[FR] DÉRIVÉS D'ACIDES AMINÉS ET LEUR UTILISATION EN TANT QUE MODIFICATEURS DE GOÛT
  申请人：FIRMENICH & CIE

  公开号：WO2021209345A1

  公开（公告）日：2021-10-21

  The present invention provides derivatives of glutamine of formula (I) and derivatives of arginine of formula (II), and the use of such compounds as flavor modifiers. The invention further provides the use of such derivatives of glutamine and arginine to enhance the salty and umami taste of ingestible compositions as ingestible compositions that include such derivatives of glutamine and arginine and bulking agents.

  本发明提供了公式(I)的谷氨酰衍生物和公式(II)的精氮酸衍生物，以及将这些化合物用作风味调节剂的用途。该发明进一步提供了利用这些谷氨酰和精氮酸衍生物增强可摄入组合物的咸味和鲜味的用途，作为包含这些谷氨酰和精氮酸衍生物以及增稠剂的可摄入组合物。
• 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS
  申请人：Parion Sciences, Inc.

  公开号：US20140170244A1

  公开（公告）日：2014-06-19

  The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.

  本发明涉及以下式的化合物： 或其药用可接受的盐，用作钠通道阻滞剂，以及含有相同化合物的组合物，制备相同化合物的方法，以及在促进粘膜表面水合和治疗包括囊性纤维化、慢性阻塞性肺病、哮喘、支气管扩张、急性和慢性支气管炎、肺气肿和肺炎等疾病的治疗方法。
• [EN] TREATMENT OF INFECTIONS<br/>[FR] TRAITEMENT D'INFECTIONS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2020064844A1

  公开（公告）日：2020-04-02

  The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety -Z to which a plurality of moieties -L2-X0D-L1-D are covalently conjugated, wherein each -D is independently an antibiotic moiety; each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated; each -X0D- is independently absent or a linkage and each -L2- is independently either a chemical bond or a spacer moiety.

  本发明涉及一种共轭物或其药用可接受的盐，或包含所述共轭物或其药用可接受的盐的药物组合物，用于预防或治疗感染的方法，其中所述共轭物不溶于水，包括一个聚合物基团-Z，其中多个基团-L2-X0D-L1-D以共价结合方式共轭，其中每个-D独立地是抗生素基团；每个-L1-独立地是连接基团，与-D以共价和可逆方式结合；每个-X0D-独立地不存在或是一个连接，每个-L2-独立地是化学键或间隔基团。

表征谱图